Aug 13, 2024
Lilly opens state-of-the-art research and development center in the Boston Seaport
Aug 08, 2024
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
Aug 01, 2024
Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity
Jul 25, 2024
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement
Jul 08, 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Jul 02, 2024
Lilly's Kisunla(TM) (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Jun 24, 2024
Lilly Declares Third-Quarter 2024 Dividend
Jun 21, 2024
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Jun 08, 2024
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
Jun 05, 2024
Lilly announces departure of Anat Ashkenazi, chief financial officer
Jun 04, 2024
Melissa Seymour to join Lilly as executive vice president of Global Quality
Jun 03, 2024
QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD
Jun 01, 2024
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
May 29, 2024
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases
May 28, 2024
Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
May 24, 2024
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines
May 23, 2024
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 21, 2024
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
May 16, 2024
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
May 15, 2024
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer